MabVax appoints Tom Varvaro to board
This article was originally published in Scrip
MabVax Therapeutics, a clinical-stage cancer immunotherapy company, has named Tom Varvaro to its board of directors as an independent director. The appointment of Mr Varvaro brings the total number of directors to seven. Mr Varvaro, age 45, has served as the CFO of ChromaDex since January 2004 and served as a director from March 2006 until May 2010. At ChromaDex, he is responsible for overseeing all aspects of the company's accounting, IT, intellectual property, and human resources.